Dynamic tests and FSH biological activity in female rats with acute nephrotic syndrome.
To investigate the pituitary-ovarian status during the acute state of the nephrotic syndrome, a sequence of experiments were undertaken in adult female rats after a single dose of the puromycin aminonucleoside (PAN). The functional condition of the hypophyseal-ovarian unit was determined in control and nephrotic rats by two dynamic tests. In the first one, 10 days after PAN or placebo administration female rats were stimulated with LHRH (300 ng/100 g body wt) and samples were collected at 0, 20, 40, 60 and 80 min after releasing factor administration. The second dynamic test, which was performed in control and nephrotic rats, consists of one (day 10 after PAN) or four (between days 7-10 after PAN) doses of hCG (8 UI), respectively. In all cases, serum samples were collected on day 10. In addition, the relative in vitro biological activity of FSH from control and nephrotic rats before and after LHRH stimulus was determined. The results reveal that after a stimulatory dose of LHRH the secretion of LH was significantly diminished in nephrotic rats at all registered times. By contrast, normal response was observed in terms of FSH secretion in nephrotic females. On the other hand, no ovarian response, in terms of progesterone or estradiol synthesis, was observed in nephrotic rats after either one or four stimuli with hCG Interestingly, in spite of the normal or high concentrations of FSH, the biological activity of FSH was totally abolished in nephrotic rats. On the whole, the results from this study indicate that the nephrotic syndrome had a harmful effect on the pituitary-ovarian unit, and strongly suggest that the endocrine dysfunction could be initiated at the hypophysial level; even though a specific ovarian damage is also predictable.
Ortiz-López
María Guadalupe
MG
Department of Reproductive Biology, Hospital Juárez de México City, Mexico.
Cárdenas
Mario
M
Zariñán
Teresa
T
Díaz-Bonilla
Laura
L
Zambrano
Elena
E
Pedraza-Chaverrí
José
J
Menjívar
Marta
M
D000208:Acute Disease; D000818:Animals; D002460:Cell Line; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D009404:Nephrotic Syndrome / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D010053:Ovary / Q000503:physiopathology*; D010902:Pituitary Gland / Q000503:physiopathology*; D011374:Progesterone / Q000097:blood; D011692:Puromycin Aminonucleoside; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D006063:Chorionic Gonadotropin; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D011692:Puromycin Aminonucleoside; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D000242:Cyclic AMP